Abstract
Introduction

Mesenchymal stem/progenitor cells (MSCs), derived from adult human bone marrow (BM), represent a leading strategy in the development of cell-based therapies for ischemic heart disease. The salutary effects of MSC administration in animal models of myocardial infarction (MI) include recovery of left ventricular function and attenuation of left ventricular remodelling, associated with augmentation of endogenous cardioprotective processes, such as neovascularization, myocyte survival and activation of resident cardiac progenitor cells
. MSC 
Materials and Methods
Full details are provided in the Supporting Information section.
In vitro biological characterization of MSCs and MPCs
The MNC fraction from human BM aspirates was used to prepare (1) MSCs by conventional, plastic-adherence isolation [10] and (2) MPCs by STRO-3-based prospective immunoselection by magnetic activated cell sorting [17] . Figure S1 Fig. 2A, B) . Left ventricular function declined following saline injections (Ϫ19%, 24 hrs versus 2 weeks, P Ͻ 0.05) (Fig. 2A) (Fig. 2B) .
Following the establishment of CFU-f, passage (P) 0 MSCs and MPCs were plated as single cell suspensions for ex vivo expansion. P4 MSCs and MPCs were compared for: (i ) CFU-f efficiency; (ii ) in vitro expansion potential; (iii ) immunophenotypic profile; (iv) genetic expression of stem cell-related transcripts and (v) developmental capacities under osteogenic, chondrogenic and adipogenic inductive conditions.
Animal studies
At the tissue level, MPC-treated hearts exhibited fewer apoptotic myocyte nuclei at the infarct border compared with saline treated hearts (P Ͻ 0.05) (Fig. 2C) , as well as less extensive areas of fibrosis (P Ͻ 0.05) (Fig. 2D ) and augmentation of peri-infarct capillary density (P Ͻ 0.05) (Fig. 2E) . (Fig. 3 (Fig. 5D ). (Fig. 6D ).
MPC engraftment in myocardial tissue at 2 weeks following transplantation was examined by immunostaining for human mitochondrial protein. However, analysis of stained tissues was confounded by the presence of false positive signals in vehicle-treated
Fig. 2 Intramyocardial injection of MPCs after MI attenuates left ventricular dysfunction and remodelling. Echocardiography was performed to assess FS (A) and LVAD (B). Myocardial sections were stained to count TUNEL ϩ apoptotic myocytes (C). Masson's Trichrome-stained sections were examined for myocardial fibrosis (D). vWF ϩ vessels per high power field were quantified (E). For (A)-(E)
,
MI hearts. These signals were likely attributable to inflammatory cells, given their localization in the infarct region and granular staining pattern (data not shown). As an alternative approach to assessing MPC engraftment, we employed PCR to detect humanspecific ribosomal protein L32 (hRPL32) in DNA extracts from rat MI hearts at 24 hrs (N ϭ 2) and 7 days (N ϭ 2) following intramyocardial injection of MPCs. MPCs were positive for hRPL32, with band intensities corresponding with cell number
MPC-CM augments EPC mobilization and homing after MI
MPC-CM contains cardioprotective and pro-angiogenic factors
The (Fig. 7C) . These morphological features were less pronounced in myocytes treated with CM ϩ ␣IL-6 MAb.
Cellular proliferation was increased in HUVECs treated with CM ϩ mIgG compared with control medium (P Ͻ 0.05) (Fig. 8A) (Fig. 8B) . CM also promoted HUVEC cord formation on growth factor-reduced Matrigel substrate (Fig. 8C and D) . (Fig. 9D) .
Neutralization of VEGF activity in CM disrupted the formation of these cord-like structures (CM ϩ ␣VEGF MAb versus CM ϩ mIgG, P Ͻ 0.05). CM increased rVSMC proliferation above controls (CM ϩ mIgG versus control, P Ͻ 0.05) (Fig. 8E). Anti-MCP-1 antibody partially reduced the proliferative effects of CM (CM ϩ ␣MCP-1 MAb versus CM ϩ mIgG, P Ͻ 0.05; CM ϩ ␣MCP-1 MAb versus control, P Ͻ 0.05). In comparison to control medium, CM stimulated increased rVSMC chemotaxis (CM ϩ mIgG versus control, P Ͻ 0.05) (Fig. 8F). Inhibition of MCP-1 activity attenuated this chemotactic effect (CM ϩ ␣MCP-1 MAb versus CM ϩ mIgG, P Ͻ 0.05). EPC proliferation was increased in cultures treated with CM, above levels observed in unstimulated controls (CM ϩ mIgG versus control, P Ͻ 0.05) (Fig. 9A). Neutralization of VEGF tended to inhibit this effect (CM ϩ mIgG versus CM ϩ ␣VEGF MAb, P Ͻ 0.05). CM also exhibited chemotactic effects on EPCs (CM ϩ mIgG versus control, P Ͻ 0.05) (Fig. 9B), which were partly attenuated in CM ϩ ␣VEGF MAb (CM ϩ ␣VEGF MAb versus CM ϩ mIgG, P Ͻ 0.05; CM ϩ ␣VEGF MAb versus control, P Ͻ 0.05). CM increased survival of EPCs cultured under hypoxic conditions (CM ϩ mIgG versus control, P Ͻ 0.05) (Fig. 9C). This protective effect was reduced by blockade of VEGF (CM ϩ ␣VEGF MAb versus CM ϩ mIgG, P Ͻ 0.05). CM stimulated formation of cordlike structures in EPCs grown on Matrigel substrate
Blockade of VEGF inhibited formation of these structures (CM ϩ ␣VEGF MAb versus CM ϩ mIgG, P Ͻ 0.05).
Fig. 5 Intramyocardial injection of CM after MI promotes neovascularization of the ischemic myocardium. Myocardial sections were immunostained to identify capillaries and arterioles. vWF ϩ vessels were counted (A). Proliferating vWF ϩ vessels were identified by co-expression of the proliferating cell nuclear antigen Ki67 (arrow heads) (B). Arterioles were immunostained with ␣SMA (C). Serial sections were double stained for ␣SMA and Ki67 (arrow heads) (D). Data are presented as mean Ϯ S.E.M. N ϭ 10-12/group. *P Ͻ 0.05.
Discussion
In the present study, we examined the biological characteristics of the culture-expanded progeny of STRO-3-immunoselected MPCs and their therapeutic potential after MI. The key findings of this study are: (1) ex vivo-grown MPCs exhibited increased proliferative capacity, gene expression for various early stem cell markers and cytokines, and differentiation efficiency compared with conventionally prepared MSCs; (2) intramyocardial injection of MPCs into rats after MI attenuated left ventricular dysfunction and remodelling, reduced myocyte apoptosis and augmented myocardial neovascularization, despite poor engraftment of transplanted cells; (3) administration of MPC-CM to the MI heart also mitigated left ventricular dysfunction and dilatation, promoted myocyte survival and hypertrophy and increased vascular density and (4) MPC-CM contained soluble factors with biological activity in cultures of cardiac myocytes, vascular cells and peripheral blood-derived EPCs.
The recently described STRO-3 monoclonal antibody has previously been shown to enrich for a subset of STRO-1 bright MNCs,
which is clonogenic and multipotential [17] . Co [5, 25] . In the acute phase after MI, transplanted cells are likely to be beset by dynamic processes including inflammation, cellular necrosis, fibrosis and metabolic and mechanical disturbances, which may impair engraftment. Our data suggest that under the [26] [27] [28] . Moreover, injection of MSC-derived factors to the post-MI heart has been shown to rapidly promote angiogenesis and cardioprotection [7, [29] [30] [31] 
cultures of HUVECs were examined in assays for proliferation (A), migration (B) and cord formation (C). Representative images of cord formation in HUVEC cultures (D). The effects of control medium, CM ϩ mouse IgG isotype control (mIgG) or CM ϩ ␣MCP-1 MAb on rat A7r5 smooth muscle cells were examined with respect to proliferation (E) and migration (F)
.
Supporting Information
Additional Supporting Information may be found in the online version of this article: 
Fig. S1 Study design of animal experiments. Animal studies were performed to examine the effects of intramyocardial (IM) delivery of MPCs (A) and CM (B) post-MI and of CM on EPC homing to the infarcted heart (C). IC: intracardiac.
